Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chase Cavayero

Urology Fort Myers, FL Doctor of Osteopathy

NPI 1326570466 CMS profile 3957759

12651 Whitehall Dr, Fort Myers, FL 33907

Open in the dashboard

General payments

$4,579

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chase Cavayero of Fort Myers, FL is reported in the CMS Open Payments database as having received $4,579 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $734 9
2024 General $232 2
2023 General $505 12
2022 General $2,376 14
2021 General $109 3
2020 General $231 2
2019 General $391 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chase Cavayero
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Chase Cavayero were reported at $734. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Chase Cavayero Urology median Middle half National median
2019 $391 $480 $147–$1,201 $163
2020 $231 $246 $87–$645 $114
2021 $109 $358 $111–$1,000 $132
2022 $2,376 $476 $143–$1,263 $149
2023 $505 $560 $168–$1,461 $160
2024 $232 $563 $170–$1,464 $164
2025 $734 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,797 19 payments
  2. Teleflex LLC $581 9 payments
  3. PROCEPT BioRobotics Corporation $382 5 payments
  4. Intuitive Surgical, Inc. $323 3 payments
  5. Coloplast Corp $145 1 payment
  6. Allergan Inc. $127 1 payment
  7. Medtronic, Inc. $93 2 payments
  8. Medtronic USA, Inc. $37 1 payment
  9. Endo Pharmaceuticals Inc. $24 1 payment
  10. Tolmar, Inc. $23 1 payment
  11. Other $47 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,832 40 payments
  2. Travel and Lodging $1,747 6 payments
Products named General payments · program years 2019–2025
  1. AMS 700 CXR RTE Kit $1,789 8 payments
  2. TACTRA $326 2 payments
  3. Da Vinci Surgical System $323 3 payments
  4. AMS $313 3 payments
  5. AQUABEAM ROBOTIC SYSTEM Urology $245 4 payments
  6. UROLIFT Interventional Urology $214 5 payments
  7. BARRIGEL $194 3 payments
  8. UROLIFT Interventional Urology $173 1 payment
  9. RESTORELLE $145 1 payment
  10. AQUABEAM ROBOTIC SYSTEM Urology $137 1 payment
  11. Other $781 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,571

Median for Urology: 1,053

Drug cost

$406,337

Median for Urology: $101,464

Branded share of claims

27.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 12 $171,692
Xtandi Enzalutamide Brand 13 $169,700
Myrbetriq Mirabegron Brand 37 $34,497
Testosterone Generic 30 $7,338
Tamsulosin Hcl Generic 391 $4,576
Finasteride Generic 291 $2,722
Potassium Citrate Er Potassium Citrate Brand 25 $2,008
Estradiol Generic 25 $1,725
Alfuzosin Hcl Er Alfuzosin Hcl Brand 63 $1,653
Bicalutamide Generic 47 $1,604

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$112,779

Of which drugs: $5,312

Medicare patients

495

Average age 75

Services billed

5,694

115 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 44%
Chronic kidney disease 39%
Diabetes 38%
Atrial fibrillation 32%
Cancer 31%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record